menu
    • menu

    Company profile for Medicinova

    NEW Drugs in Dev: 6
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MediciNova is a biopharmaceutical company that is developing novel therapeutics with a primary focus on neurology, respiratory, and liver diseases with unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MedicinovaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4275 Executive Square, Suite 300 La Jolla, CA 92037
    Telephone
    Telephone
    (858) 373-1500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://medicinova.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/medicinova-inc.
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medicinova To Participate At The 38th Annual ROTH Conference
    Medicinova To Participate At The 38th Annual ROTH Conference

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256108/7767/en/MediciNova-to-Participate-at-the-38th-Annual-ROTH-Conference.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    MediciNova Completes 100-PT SEANOBI EAP for MN-166 (Ibudilast)
    MediciNova Completes 100-PT SEANOBI EAP for MN-166 (Ibudilast)

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229186/7767/en/MediciNova-Announces-100-Patients-Enrolled-in-SEANOBI-Study-Expanded-Access-Program-EAP-Evaluating-MN-166-ibudilast-in-ALS-patients.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    CEO Sends 2026 New Year's Greetings
    CEO Sends 2026 New Year's Greetings

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213709/7767/en/2026-New-Year-s-Greetings-from-the-CEO.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207535/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-Evaluating-MN-166-ibudilast-in-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Medicinova Updates MN-166 Phase 2/3 ALS Trial At ALS/MND
    Medicinova Updates MN-166 Phase 2/3 ALS Trial At ALS/MND

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201345/7767/en/MediciNova-Announces-Update-and-Basic-Characteristic-Randomized-Patients-of-Phase-2-3-Clinical-Trial-of-MN-166-Ibudilast-in-ALS-COMBAT-ALS-Clinical-Trial-Presented-at-the-36th-Inte.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Message From The CEO To Medicinova Shareholders
    Message From The CEO To Medicinova Shareholders

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3197534/7767/en/Message-from-the-CEO-to-MediciNova-Shareholders.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search